midazolam and su 11248

midazolam has been researched along with su 11248 in 5 studies

Research

Studies (5)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	5 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Baker, SD; Chen, Z; den Hartigh, J; den Hollander, M; Gelderblom, H; Guchelaar, HJ; König-Quartel, JM; Ploeger, BA; van Erp, NP; Zandvliet, AS	1
Akiyama, Y; Fujita, K; Murayama, N; Sasaki, Y; Sugiyama, M; Yamazaki, H	1
de Wit, D; den Hartigh, J; den Hollander, M; Gelderblom, H; Guchelaar, HJ; Hessing, T; König-Quartel, JM; Sparreboom, A; van Erp, NP	1
Balakrishnar, B; Bennink, RJ; Daali, Y; Eechoute, K; Gurney, H; Huitema, AD; Kam, BL; Kloth, JS; Klümpen, HJ; Mathijssen, RH; Samer, CF; Schellens, JH; Wong, M; Yu, H; Zwinderman, AH	1

Reviews

1 review(s) available for midazolam and su 11248

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Trials

1 trial(s) available for midazolam and su 11248

Article	Year
Marginal increase of sunitinib exposure by grapefruit juice. Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Beverages; Biological Availability; Citrus paradisi; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Labeling; Female; Food-Drug Interactions; Humans; Indoles; Male; Midazolam; Middle Aged; Neoplasms; Pyrroles; Sunitinib	2011

Article

Year

Marginal increase of sunitinib exposure by grapefruit juice.

Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:3

Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Beverages; Biological Availability; Citrus paradisi; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Labeling; Female; Food-Drug Interactions; Humans; Indoles; Male; Midazolam; Middle Aged; Neoplasms; Pyrroles; Sunitinib

2011

Other Studies

3 other study(ies) available for midazolam and su 11248

Article	Year
Sorafenib and sunitinib, two anticancer drugs, inhibit CYP3A4-mediated and activate CY3A5-mediated midazolam 1'-hydroxylation. Drug metabolism and disposition: the biological fate of chemicals, 2011, Volume: 39, Issue:5 Topics: Antineoplastic Agents; Benzenesulfonates; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Humans; Hydroxylation; Indoles; Liver; Microsomes, Liver; Midazolam; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib	2011
Midazolam as a phenotyping probe to predict sunitinib exposure in patients with cancer. Cancer chemotherapy and pharmacology, 2014, Volume: 73, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Cytochrome P-450 CYP3A; Female; Humans; Indoles; Male; Midazolam; Middle Aged; Neoplasms; Phenotype; Prospective Studies; Pyrroles; Sunitinib	2014
Predictive value of CYP3A and ABCB1 phenotyping probes for the pharmacokinetics of sunitinib: the ClearSun study. Clinical pharmacokinetics, 2014, Volume: 53, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Biotransformation; Cytochrome P-450 CYP3A; Female; Humans; Hypnotics and Sedatives; Indoles; Male; Midazolam; Middle Aged; Phenotype; Prospective Studies; Pyrroles; Radiopharmaceuticals; Sunitinib; Technetium Tc 99m Sestamibi	2014